Many clinician researchers are attempting to "repurpose" old treatments for COVID-19. How shold we evaluate purported positive findings in a small, but rigorous, clinical trial?
Fast to the wrong answer is not a good business or scientific strategy. Slow, but rigorous, analysis does not meet business or scientific needs either. It has to be "and."
Published research from respectable journals and reported by renowned press outlets can be very misleading and of questionable importance. But it helps keep funding for the researchers and readership for the news media.